More Studies on Outcomes Using Biochemical Diagnostic Tests Are Needed: Findings from the Danish Society of Clinical Biochemistry

To the Editor:
The results of biochemical tests often lead to diagnostic and therapeutic interventions, and the real value of a test can be assessed only by taking into account the subsequent health outcomes. The importance of outcomes studies, and the challenges in performing them, was reviewed by Bruns in 2001 (1 ) , who argued that this type of study should be performed more frequently, and that such studies should be used to determine whether new tests should be implemented in clinical practice.
To investigate the extent to which this recommendation has been realized, a working group on evidence-based clinical biochemistry established by the Danish Soci To identify reports of outcome studies, 2 authors manually went through reports published in each of the journals within a 12-month period. Detailed information on original full-length reports considered diagnostic biochemical outcome studies was registered together with the total number of original articles. Technical Briefs, Letters, Short Communications, Editorials, and Reviews were not included. When there were discrepancies in report selection by the 2 authors scrutinizing the same journal issues, a consensus decision was made in the entire author group. Selected outcomes reports were classified as investigating (A) direct clinical mortality or morbidity; (B) other clinical variables such as length of hospital stay, readmission rate, or satisfaction with care; or (C) economic outcomes.
A total of 829 original articles were registered, of which only 7 studies (0.8%) were classified as diagnostic biochemical outcome studies (Table 1) An outcome study addresses the question of whether use of the studied intervention (in this case a laboratory test) leads to an anticipated outcome (1, 2 ) . The randomized controlled trial is a powerful design strategy for such studies, avoiding many pitfalls that occur with other study designs (2 ) . Three of the outcome studies identified in this pilot study used a randomized controlled trial design that involved some variant of a test-treat-counsel policy to be compared with a policy not involving the testing element.
Before-and-after diagnostic assessment of clinical impact is another appropriate design for evaluating clinical outcomes of the use of laboratory tests (3 ) , as elegantly demonstrated in the study by Stramer et al. (Table 1 ). This study investigated the effect of prospective screening of all blood donors for West Nile virus, and the results indicated that carriers of the virus were eliminated from the US Red Cross blood supplies, and no infections were detected among recipients after the introduction of this screening program.
We identified good examples of diagnostic biochemical outcome studies, but the absolute number of these studies was disappointingly low, indicating insufficient documentation of the health outcomes produced by diagnostic biochemical analyses. This insufficiency is probably attributable to multifaceted causes. An important aspect is undoubtedly the complexity and high costs of outcome studies (1, 4 ) , because many steps lie between test findings and outcome. Research is needed that addresses (1-4 ) , and in the textbook Evidence-Based Laboratory Medicine the chapter on assessment of outcomes is especially relevant (5 ).
Our purpose is to highlight the importance of moving from diagnostic accuracy studies to evaluations of the effects of test results on clinical decision-making and subsequent health outcomes. In agreement with other investigators (1-5 ), we support efforts to increasing the use of outcome studies to enhance the effectiveness of healthcare policy and decision-making. 
Electrospray Ionization Mass Spectrometric Analysis of the Globin Chains in Hemoglobin Heterozygotes Can Detect the Variants HbC, D, and E
To the Editor:
We would like to point out that 2 recent articles in this journal about human hemoglobin (Hb) analysis (1, 2 ) give the false impression that variant globin chains with Ͻ6 Da mass difference from normal cannot be detected in heterozygotes by electrospray ionization mass spectrometry (ESI-MS). Kleinert et al.
(1 ) state: "Two important drawbacks of the MS methods should be mentioned. First, its insufficient resolution prevents the detection of Hb mutations with small mass differences of the globin chains. The precision of normal low-resolution mass measurements was insufficient to distinguish the wild-type ␤-chain from several ␤-chain variants such as HbC, D, or E". Brennan (2 ) comments similarly by stating that whereas traditional methods readily detect the majority of common variants, such as HbC, HbD, or HbE, "the substitutions involved in these, and similar charge variants (Glu7Lys, Glu7Gln, Asp7Asn, and Lys7 Gln) involve mass changes of 1 Da or less, and are not detectable by mass spectrometry." Kleinert et al.
(1 ) also state: "Second, MS as described here is only a qualitative technique, and in particular, minor Hb fractions such as HbA 1c or HbA 2 , which are important for diagnosis of diabetes mellitus or thalassemias, respectively, cannot be quantified."
While we agree that ESI-MS cannot detect the zero mass change mutations (Lys7Gln and Leu3 Ile), we maintain it is not necessary to resolve the variant and normal globin chains in heterozygotes to detect variants that differ in mass from normal by Ϯ1 Da (Glu7Lys, Glu7Gln, Asp7Asn, Asn3 Ile). In 2003, Rai et al. (3 ) showed that variants differing by 1 Da from normal can be detected if present at Ͼ10% abundance. In that report, the normal ␤-chain mass was determined with a precision of 0.05 Da SD, which resulted in a 0.10 Da mass change being detectable with 95% confidence. We routinely analyze Hb on a quadrupole instrument and, owing to improved performance since 2003, generally achieve Յ0.03 Da SD on the normal ␤-chain when using the ␣-chain for internal calibration. For example, 50 normal blood samples analyzed over the last 4 months gave a mean ␤-chain mass of 15 867.255 Da (0.026 Da SD).
